Sandoz Group AG (Sandoz Group AG) Equity-to-Asset : 0.45 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sandoz Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $8,645 Mil. Sandoz Group AG's Total Assets for the quarter that ended in Dec. 2023 was $19,430 Mil. Therefore, Sandoz Group AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.45.

The historical rank and industry rank for Sandoz Group AG's Equity-to-Asset or its related term are showing as below:

SDZNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45 Med: 0.47 Max: 0.5
Current: 0.45

During the past 2 years, the highest Equity to Asset Ratio of Sandoz Group AG was 0.50. The lowest was 0.45. And the median was 0.47.

SDZNY's Equity-to-Asset is ranked worse than
66.67% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SDZNY: 0.45

Sandoz Group AG Equity-to-Asset Historical Data

The historical data trend for Sandoz Group AG's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Equity-to-Asset Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Equity-to-Asset

0.50

0.45

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Equity-to-Asset	0.50	0.45

Competitive Comparison of Sandoz Group AG's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Equity-to-Asset falls into.

Sandoz Group AG Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sandoz Group AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	8645	/	19430
	=	0.44

Sandoz Group AG's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	8645	/	19430
	=	0.44

Sandoz Group AG (OTCPK:SDZNY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sandoz Group AG Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024